Related Experiment Video
Updated: May 29, 2026
03:07
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study
Zejian Yang1,2, Peng Ni1,2, Yu Wang1,2
1Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Cancer Medicine
|May 28, 2026
Summary
Neoadjuvant chemotherapy (Neo-CT) shows survival benefits for select male breast cancer (MaBC) patients, particularly those achieving pathological complete response (pCR). pCR is linked to early-stage and hormone receptor-negative MaBC, improving overall and breast cancer-specific survival.
Area of Science:
- Oncology
- Medical Research
Background:
- The survival advantage of neoadjuvant chemotherapy (Neo-CT) in male breast carcinoma (MaBC) is not well-established.
- Identifying specific patient subgroups who benefit from Neo-CT is crucial for treatment optimization.
Purpose of the Study:
- To evaluate the impact of Neo-CT on therapeutic response and prognosis in male breast carcinoma patients.
- To define the patient population that may benefit from Neo-CT and identify predictors of pathological complete response (pCR).
Main Methods:
- Utilized data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.
- Employed Kaplan-Meier analysis, Cox proportional hazards model, and binary logistic regression.
- Analyzed outcomes for 4171 MaBC patients, categorizing them by Neo-CT and adjuvant chemotherapy regimens.
Main Results:
- Achieving pathological complete response (pCR) was associated with significantly improved 5-year and 10-year overall survival (OS) and breast cancer-specific survival (BCSS).
- pCR was more likely in patients with stage I-II disease and hormone receptor (HR)-negative MaBC, with a pCR rate of 66.67% in this subgroup.
- Out of 4171 patients, 12.12% achieved pCR.
Conclusions:
- Neoadjuvant chemotherapy can offer a survival benefit in male breast carcinoma, especially when pCR is achieved.
- Early-stage (I-II) and hormone receptor-negative MaBC patients are potential candidates for Neo-CT, as they show higher pCR rates.
- Further research is warranted to refine Neo-CT selection criteria for male breast cancer patients.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...